Trial reportAnnals of surgical oncology2023
Use of Superparamagnetic Iron Oxide (SPIO) Versus Conventional Technique in Sentinel Lymph Node Detection for Breast Cancer: A Randomised Controlled Trial.
Trial report in Annals of surgical oncology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 1 synthesis or guideline pooled it, 17 citations in OpenAlex.
- Superparamagnetic Iron Oxide Tracer: A Magnetic Match to Gold Standard in Melanoma Sentinel Lymph Node Biopsy-A Systematic Review and Meta-Analysis.Journal of surgical oncology · 2025Pooled it
- Prospective Clinical Trial on Expanding the Eligibility Criteria for Targeted Axillary Dissection after Neoadjuvant Systemic Therapy in Breast Cancers with Advanced Nodal Disease.Annals of surgical oncology · 2026Trial
- A Multicenter Non-Inferiority Randomized Controlled Trial of Sentinel Lymph Node Biopsy in Early Breast Cancer: Conventional Dual Tracer Versus Superparamagnetic Iron Oxide.World journal of surgery · 2026Trial
- The Past, Present, and Future of Sentinel Lymph Node Biopsy in Breast Cancer.Annals of surgical oncology · 2026Review
- Can we now save the neck of OSCC T1-T2 patients? A narrative review of whether experimental techniques are on the way to clinical application.Exploration of targeted anti-tumor therapy · 2026Review
- Postoperative Chylous Leakage in Breast Cancer Patients: A Multicentre Case Series.Breast care (Basel, Switzerland) · 2025Article
- Article
- Review
- Ultra-low dose superparamagnetic iron oxide nanoparticle injection for sentinel lymph node detection in breast cancer: prospective cohort study.The British journal of surgery · 2025Article
- Is the Superparamagnetic Approach Equal to Radioisotopes in Sentinel Lymph Node Biopsy? The Over-Collecting Node Issue in Breast Cancer Patients.Journal of clinical medicine · 2025Article
- Recent innovations in nanomedicine and nano-based techniques for the treatment of breast cancer.BioImpacts : BI · 2025Review
- Emerging Applications of Nanoparticles in the Diagnosis and Treatment of Breast Cancer.Journal of personalized medicine · 2024Review
- Recent trends in preparation and biomedical applications of iron oxide nanoparticles.Journal of nanobiotechnology · 2024Review
- Intramammary Tumor Location and Ipsilateral Lymphatic Spread in Early Breast Cancer Patients Using One-Step Nucleic Acid Amplification (OSNA) Assay.The breast journal · 2024Observational
- Optical Imaging in Human Lymph Node Specimens for Detecting Breast Cancer Metastases: A Review.Cancers · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe objective of this study is to compare the efficacy of the superparamagnetic iron oxide (SPIO)-guided and standard techniques for sentinel lymph node (SLN) detection in early breast cancer. Multiple inferiority trials have concluded the non-inferiority of SPIO to the conventional radioisotope technique, with or without blue dye, in detecting SLNs. PATIENTS AND
methodsFrom July 2018 to August 2022, patients clinically diagnosed with node-negative invasive breast cancer were randomised into the study group (SPIO) and control group (radioisotope and blue dye). Patient data and disease characteristics were prospectively collected. SLN detection rates were compared between the two groups.
resultsA total of 282 patients undergoing 288 sentinel lymph node biopsy (SLNB) procedures were recruited, and 144 SLNB procedures were randomised into each group. The baseline patient and disease characteristics were comparable. SLN localisation failed in one patient in each group; the success rate of SLNB was 99.3%. The SPIO group demonstrated a higher mean number of SLNs harvested (3.3 versus 2.8, p = 0.039) and longer mean procedure duration (33.1 min versus 22.3 min, p = 0.01) than the control group did. In the study group, the concordance rates per patient and node were 99.3% and 94.6%, respectively. Sixty-seven positive SLNs were detected in 37 patients. The concordance rates per malignant SLNB procedure and positive SLN were 97.3% and 96.8%, respectively.
conclusionSingle-tracer SPIO-guided SLNB was non-inferior to the dual technique (radioisotope and blue dye) and could safely replace the gold standard for SLN mapping in early breast cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.